Lessons from a French collaborative case-control study in cystic fibrosis patients during the 2009 A/H1N1 influenza pandemy

Julie Bucher, Pierre-Yves Boelle, Dominique Hubert, Muriel Lebourgeois, Nathalie Stremler, Isabelle Durieu, François Bremont, Eric Deneuville, Bertrand Delaisi, Harriet Corvol, Laurence Bassinet, Dominique Grenet, Natacha Remus, Marie Véronique Vodoff, Véronique Boussaud, Françoise Troussier, Marianne Leruez-Ville, Jean-Marc Treluyer, Odile Launay, Isabelle Sermet-Gaudelus, Julie Bucher, Pierre-Yves Boelle, Dominique Hubert, Muriel Lebourgeois, Nathalie Stremler, Isabelle Durieu, François Bremont, Eric Deneuville, Bertrand Delaisi, Harriet Corvol, Laurence Bassinet, Dominique Grenet, Natacha Remus, Marie Véronique Vodoff, Véronique Boussaud, Françoise Troussier, Marianne Leruez-Ville, Jean-Marc Treluyer, Odile Launay, Isabelle Sermet-Gaudelus

Abstract

Background: Viral infections such as influenza are thought to impact respiratory parameters and to promote infection with Pseudomonas aeruginosa in patients with cystic fibrosis (CF). However, the real morbidity of the influenza virus in CF needs to be further investigated because previous studies were only observational.

Methods: CF patients were included in a case-control study (n = 44 cases and n = 371 controls) during the 2009 pandemic A/H1N1 influenza. Cases were patients with polymerase reaction chain-confirmed influenza A/H1N1 infection. Controls did not report any influenza symptoms during the same period. Sputum colonization and lung function were monitored during 1 year after inclusion.

Results: Cases were significantly younger than controls (mean(SD) 14.9 years(11) versus 20.1 years (13.2) and significantly less frequently colonized with P. aeruginosa (34 % versus 53 %). During influenza infection, 74 % of cases had pulmonary exacerbation, 92 % had antibiotics adapted to their usual sputum colonization and 82 % were treated with oseltamivir. Two cases required lung transplantation after A/H1N1 infection (one had not received oseltamivir and the other one had been treated late). The cases received a mean number of antibiotic treatments significantly higher during the year after the influenza infection (mean(SD) 2.8 (2.4) for cases versus 1.8(2.1) for controls; p = 0.002). An age-matched comparison did not demonstrate any significant modification of bronchopulmonary bacterial colonization during the year after influenza infection nor any significant change in FEV1 at months 1, 3 and 12 after A/H1N1 infection.

Conclusions: Our results do not demonstrate any change in sputum colonization nor significant lung disease progression after pandemic A/H1N1 influenza.

Trial registration: Clinical Trials.gov registration number: NCT01499914.

References

    1. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005;352:1992–2001. doi: 10.1056/NEJMra043184.
    1. Abman SH, Ogle JW, Butler-Simon N, Rumack CM, Accurso FJ. Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr. 1988;113:826–30. doi: 10.1016/S0022-3476(88)80008-8.
    1. Armstrong D, Grimwood K, Carlin JB, Carzino R, Hull J, Olinsky A, et al. Severe viral respiratory infections in infants with cystic fibrosis. Pediatr Pulmonol. 1998;26:371–9. doi: 10.1002/(SICI)1099-0496(199812)26:6<371::AID-PPUL1>;2-N.
    1. Conway SP, Simmonds EJ, Littlewood JM. Acute severe deterioration in cystic fibrosis associated with influenza A virus infection. Thorax. 1992;47:112–4. doi: 10.1136/thx.47.2.112.
    1. Esther CR, Jr, Lin FC, Kerr A, Miller MB, Gilligan PH. Respiratory viruses are associated with common respiratory pathogens in cystic fibrosis. Pediatr Pulmonol. 2014;49:926–31. doi: 10.1002/ppul.22917.
    1. Etherington C, Naseer R, Conway SP, Whitaker P, Denton M, Peckham DG. The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation. J Cyst Fibros. 2014;13:49–55. doi: 10.1016/j.jcf.2013.06.004.
    1. Flight WG, Bright-Thomas RJ, Tilston P, Mutton KJ, Guiver M, Morris J, et al. Incidence and clinical impact of respiratory viruses in adults with cystic fibrosis. Thorax. 2014;69:247–53. doi: 10.1136/thoraxjnl-2013-204000.
    1. Goffard A, Lambert V, Salleron J, Herwegh S, Engelmann I, Pinel C, et al. Virus and cystic fibrosis: rhinoviruses are associated with exacerbations in adult patients. J Clin Virol. 2014;60:147–53. doi: 10.1016/j.jcv.2014.02.005.
    1. Hoek RA, Paats MS, Pas SD, Bakker M, Hoogsteden HC, Boucher CA, et al. Incidence of viral respiratory pathogens causing exacerbations in adult cystic fibrosis patients. Scand J Infect Dis. 2013;45:65–9. doi: 10.3109/00365548.2012.708942.
    1. Robinson KM, Kolls JK, Alcorn JF. The immunology of influenza virus-associated bacterial pneumonia. Curr Opin Immunol. 2015;34C:59–67. doi: 10.1016/j.coi.2015.02.002.
    1. Ortiz JR, Neuzil KM, Victor JC, Wald A, Aitken ML, Goss CH. Influenza-associated cystic fibrosis pulmonary exacerbations. Chest. 2010;137:852–60. doi: 10.1378/chest.09-1374.
    1. Smyth AR, Smyth RL, Tong CY, Hart CA, Heaf DP. Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis. Arch Dis Child. 1995;73:117–20. doi: 10.1136/adc.73.2.117.
    1. van Ewijk BE, van der Zalm MM, Wolfs TF, Fleer A, Kimpen JL, Wilbrink B, et al. Prevalence and impact of respiratory viral infections in young children with cystic fibrosis: prospective cohort study. Pediatrics. 2008;122:1171–6. doi: 10.1542/peds.2007-3139.
    1. Cohen TS, Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat Med. 2012;18:509–19. doi: 10.1038/nm.2715.
    1. Viviani L, Assael BM, Kerem E. Impact of the A (H1N1) pandemic influenza (season 2009-2010) on patients with cystic fibrosis. J Cyst Fibros. 2011;10:370–6. doi: 10.1016/j.jcf.2011.06.004.
    1. Ministère de la Santé et des Sports. Grippe: information aux professionnels. Prise en charge de vos patients (September 17th, 2009): . Acccessed date: 20 January 2016
    1. Bilton D, Canny G, Conway S, Dumcius S, Hjelte L, Proesmans M, et al. Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. J Cyst Fibros. 2011;10(Suppl 2):S79–81. doi: 10.1016/S1569-1993(11)60012-X.
    1. Boëlle PY, Viviani L, Busson PF, Olesen HV, Ravilly S, Stern M, et al. Reference percentiles for FEV(1) and BMI in European children and adults with cystic fibrosis. Orphanet journal of rare diseases. 2012;7:64. doi: 10.1186/1750-1172-7-64.
    1. Brammer L, Blanton L, Epperson S, Mustaquim D, Bishop A, Kniss K, et al. Surveillance for Influenza during the 2009 Influenza A (H1N1) Pandemic–United States, April 2009–March 2010. Clin Infect Dis. 2011;52:S27–35. doi: 10.1093/cid/ciq009.
    1. Vaux S, Brouard C, Fuhrman C, Turbelin C, Cohen JM, Valette M, et al. Dynamics and impact of the A(H1N1) 2009 epidemic in metropolitan France, 2009-2010. Bull Epid Hebd. 2010;24-26.
    1. Launay O, Boelle PY, Krivine A, Grenet D, Boussaud V, Rémus N, et al. Factors associated with humoral immune response to pandemicA/H1N1(v) 2009 influenza vaccine in cystic fibrosis. Vaccine. 2014;32:4515–21. doi: 10.1016/j.vaccine.2014.06.010.
    1. Colombo C, Battezzati PM, Lucidi V, Magazzù G, Motta V, Alicandro G, et al. Influenza A/H1N1 in patients with cystic fibrosis in Italy: a multicentre cohort study. Thorax. 2011;66:260–1. doi: 10.1136/thx.2010.157032.
    1. France MW, Tai S, Masel PJ, Moore VL, McMahon TL, Ritchie AJ, et al. The month of July: an early experience with pandemic influenza A (H1N1) in adults with cystic fibrosis. BMC Pulm Med. 2010;10:8.
    1. Nash EF, Whitmill R, Barker B, Rashid R, Whitehouse JL, Honeybourne D. Clinical outcomes of pandemic (H1N1) 2009 influenza (swine flu) in adults with cystic fibrosis. Thorax. 2011;66:259. doi: 10.1136/thx.2010.140822.
    1. Whitaker P, Etherington C, Denton M, Conway S, Peckham D. A/H1N1 flu pandemic. A/H1N1 and other viruses affecting cystic fibrosis. BMJ. 2009;339:b3958. doi: 10.1136/bmj.b3958.
    1. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med. 2010;362:1708–19. doi: 10.1056/NEJMra1000449.
    1. Lemaitre M, Carrat F. Comparative age distribution of influenza morbidity and mortality during seasonal influenza epidemics and the 2009 H1N1 pandemic. BMC Infect Dis. 2010;10:162. doi: 10.1186/1471-2334-10-162.
    1. Sehgal N, Woodhead M. Predicting the unpredictable: is it possible clinically to separate H1N1 from non-H1N1 community-acquired pneumonia? Thorax. 2011;66:187–8. doi: 10.1136/thx.2010.157404.
    1. Yamamoto T, Ihashi M, Mizoguchi Y, Kaneno H, Yamamoto K, Inoue Y, et al. Early therapy with neuraminidase inhibitors for influenza A (H1N1) pdm 2009 infection. Pediatr Int. 2013;55:714–21. doi: 10.1111/ped.12154.
    1. Tautenberg JK, Morens DM. The pathology of influenza virus infections. Annu Rev Pathol. 2008;3:499–522. doi: 10.1146/annurev.pathmechdis.3.121806.154316.
    1. Iwasaki A, Pillai PS. Innate immunity to influenza virus infection. Nat Rev Immunol. 2014;14:315–28. doi: 10.1038/nri3665.
    1. Chattoraj SS, Ganesan S, Jones AM, Helm JM, Comstock AT, Bright-Thomas R, et al. Rhinovirus infection liberates planktonic bacteria from biofilm and increases chemokine responses in cystic fibrosis airway epithelial cells. Thorax. 2011;66(4):333–9. doi: 10.1136/thx.2010.151431.
    1. Petersen NT, Hoiby N, Mordhorst CH, Lind K, Flensborg EW, Bruun B. Respiratory infections in cystic fibrosis patients caused by virus, chlamydia and mycoplasmapossible synergism with Pseudomonas aeruginosa. Acta Paediatr Scand. 1981;70:623–8.
    1. WHO (2013) Epidemiological and virological situation update of the 2012/2013 influenza season in the WHO European Region. WHO Europe Publications. Available:.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner